Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,795 matching trials from the live ClinicalTrials.gov search.
Conditions
Pancreatic Cancer Metastatic
Interventions
Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin), C3 (Metformin, Simvastatin, and Digoxin) only
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Acute Ischemic Stroke From Large Vessel Occlusion
Interventions
ANA Funnel Catheter, Control
Device
Lead sponsor
Anaconda Biomed S.L.
Industry
Eligibility
22 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Jacksonville, Florida • Atlanta, Georgia • Park Ridge, Illinois + 8 more
Completed Not applicable Interventional

Finger Movement Training After Stroke

NCT05621980
Conditions
Stroke
Interventions
Actuated Virtual Keyboard (AVK) system, Occupational Therapy (OT)
Behavioral
Lead sponsor
North Carolina State University
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
Conditions
Cystic Fibrosis
Interventions
VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
Conditions
Diabetic Macular Edema
Interventions
Bevacizumab, dexamethasone intravitreal implant
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Prenatal Exposure Effects Psychophysiology Study

NCT01134770
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine, Nab Paclitaxel, Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
Drug · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Acromegaly
Interventions
Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Atorvastatin
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia
Conditions
PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Interventions
HWK-016, MUCIN-16-targeted ADC, Bevacizumab
Drug
Lead sponsor
Whitehawk Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Sarasota, Florida + 9 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
66
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
Conditions
COPD
Interventions
CALM Breathing, Traditional outpatient PR
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
New York, New York
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Conditions
Obsessive-Compulsive Disorder
Interventions
Group Improv sessions, Group Exposure and Response Prevention (ERP) Therapy
Other · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stanford, California
Conditions
Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis
Interventions
XL495, ADC cytotoxic agents
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Conditions
Advanced Cancers
Interventions
Azacitidine, Lenalidomide, Grifola Frondosa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 and Gardasil, rLP2086, Gardasil
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 17 Years
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
87
States / cities
Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Conditions
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more